louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03516786: Quality of Recovery After Quadratus Lumborum Block for Cesarean Section.
Official title: Quality of Recovery After Quadratus Lumborum Block for Cesarean Section: A Prospective Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Pain
Lead sponsor: Corniche Hospital
Sponsor class: OTHER
First posted: 2018-05-04
Enrollment: 25
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Twenty five parturients, with American Society of Anesthesiologists (ASA) physical status II, with normal singleton pregnancy, at 37 weeks gestation or more, admitted to Corniche Hospital for elective caesarean section under spinal anesthesia

Brief summary: The aim of this prospective study is to evaluate the recovery after cesarean section in patients who will receive Quadratus Lumborum Block (QLB) as a part of multimodal analgesia using Postoperative quality of recovery scale.

Detailed description: Several researchers had evaluated the effectiveness of QLB in controlling postoperative pain in different patient populations. In these studies, the effectiveness of the QLB was mainly assessed by postoperative pain scores and analgesia consumption, rather than adapting any of the more comprehensive recovery scales .

Postoperative quality of recovery scale (PostopQRS) is a relatively new recovery score, which was first published on 2010, and was designed to be a tool for assessment of multiple domains in recovery. In this assessment tool, recovery was defined as return to the pre-surgery base line scores or better.

The aim of this prospective study is to evaluate the recovery after cesarean section in patients who will receive Quadratus Lumborum Block QLB as a part of multimodal analgesia using Postoperative quality of recovery scale.

Eligibility criteria: Inclusion Criteria:

American Society of Anesthesiologists (ASA) physical status II, normal singleton pregnancy, 37 weeks gestation or more Scheduled for elective cesarean section

Exclusion Criteria:

* Patients refusing spinal
* Patients with BMI \>35 kg/m2).
* Expected difficult surgery (\> 3 previous sections, abnormal placentation, prolonged surgery more than 2 hours from skin to end) and Estimated Blood Loss more than 1500).
* Expected difficult spinal anesthesia.
* Abnormal coagulation and other contraindications for spinal anesthesia and/or QLB
* Patient with chronic pain.
* Patient treated from psychosis.
* Patients with communication, language barriers .

Primary outcomes:
measure: change from baseline postoperative quality of recovery score
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: Corniche Hospital
Study officials:
affiliation: Corniche Hospital
name: Waleed Riad, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Corncihe hospital
name: Amr Maher, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03534986: Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements
Official title: Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystic Fibrosis
Bronchiectasis
Lead sponsor: International Biophysics Corporation
Sponsor class: INDUSTRY
First posted: 2018-05-23
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The impact of high-frequency chest wall oscillation therapy on spirometry values (Forced Expiratory Volume, Forced Vital Capacity, Peak Expiratory Flow, Forced Expiratory Flow and Tidal Volume is investigated during use of several products and comparing to baseline values.

Detailed description: The study will be broken into three (3) arms:

* AffloVest® \& The Vest®
* AffloVest® \& inCourage®
* AffloVest® \& SmartVest® Subjects will be randomly assigned to an arm. Within each arm, the order of products will be also randomized.

Baseline spirometry (Forced Expiratory Volume (FEV1), Forced Vital Capacity (FVC), Peak Expiratory Flow (PEF), Forced Expiratory Flow (FEF25-75%) and Tidal Volume (TV)) will be taken at the beginning, middle and end of each series of measurements with each subject, without any device on the subject.

A product (AffloVest or Compressor-based vest) will be placed onto subject and turned ON to the highest frequency and intensity settings. Then the subject will be given a certain period of time to adjust and spirometry measurements will then be repeated, then The product will be removed and the subject will be allowed a recovery period, then the other product will be placed on the subject, turned ON and spirometry measurements will repeated.

Eligibility criteria: Inclusion Criteria:

* Healthy subject, ages 18 - 50

Exclusion Criteria:

* Non-ambulatory, diagnosed neuromuscular disorder, currently using any type of oscillation vest therapy, diagnosed co-morbid condition (i.e. lung cancer, other lung disorder or disease), currently enrolled in a medical research study, non-English speaking

Primary outcomes:
measure: TV
timeFrame: 30 minutes
measure: PEF
timeFrame: 30 minutes
measure: FVC
timeFrame: 30 minutes
measure: FEV1
timeFrame: 30 minutes
measure: FEF25-75%
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Kissimmee
country: United States
facility: PDS Research
state: Florida
Study officials:
affiliation: PDS Research
name: Thomas W O'Brien, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04096586: Effects of Watermelon Consumption on Satiety and Digestive Health
Official title: Effects of Watermelon Consumption on Satiety and Digestive Health
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Satiety
Lead sponsor: San Diego State University
Sponsor class: OTHER
First posted: 2019-09-20
Enrollment: 80
Sex: ALL
Minimum age (years): 10
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The objective of the proposed research is to determine the effects of watermelon (fruit and rind blenderized) on satiety, metabolic markers, bowel habits, microbiome and weight management in children and adults


Eligibility criteria: Inclusion Criteria:

* Generally healthy subjects

Exclusion Criteria:

* Smoker
* Pregnant woman
* Required dietary supplement use
* Required medication of metabolic disorders
* Allergy to watermelon

Primary outcomes:
measure: Change of satiety
timeFrame: 0 and 20, 40, 60, 90 and 120 minutes post juice consumption
measure: Change of glucose level
timeFrame: 0 and 20, 40, 60, 90 and 120 minutes post juice consumption
measure: Change of insulin level
timeFrame: 0 and 20, 40, 60, 90 and 120 minutes post juice consumption
measure: Change of triglyceride level
timeFrame: Baseline and week 8
Secondary outcomes:
measure: Change of alpha diversity in microbiome
timeFrame: Baseline and week 8
Other outcomes:
Locations:
city: San Diego
country: United States
facility: School of Exercise and Nutritional Sciences, SDSU
state: California
Study officials:
References:
Clinical trial NCT05024786: The Effect of CQI on the Outcome of Patients Supported With ECMO
Official title: The Effect of Continuous Quality Improvement on the Outcome of Patients Supported With Extracorporeal Membrane Oxygenation in ICU
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory and Circulation Failure
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
First posted: 2021-08-27
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients over 18 years old who received ECMO support in the centers between January 2015 and April 2021 were included, not including patients waiting for transplantation with ECMO.

Brief summary: This was a prospective observational study in comparison with a retrospective control group(Jan 2015 to Jun 2019). Two ICUs in China were included. The continuous quality improvement (CQI)strategies were implemented from Jul 2019 to Jun 2021(CQI group). The mortalities of ECMO patients was compared between the CQI group and the control group.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years old who received ECMO support in the centers

Exclusion Criteria:

* patients waiting for transplantation with ECMO.

Primary outcomes:
measure: The mortality of patients supported with ECMO
timeFrame: January, 2021 to July, 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Qingdao
country: China
facility: The Affiliated Hospital of Qingdao University
state: Shandong
Study officials:
References:
citation: Jing Y, Yuan Z, Zhou W, Han X, Qi Q, Song K, Xing J. A phased intervention bundle to decrease the mortality of patients with extracorporeal membrane oxygenation in intensive care unit. Front Med (Lausanne). 2022 Oct 17;9:1005162. doi: 10.3389/fmed.2022.1005162. eCollection 2022.
Clinical trial NCT03833739: Comparison Between 2 Protocols for the Treatment of Class II Division 2 Malocclusion
Official title: A Prospective Randomized Clinical Trial to Compare Between Two Leveling and Alignment Protocols for the Treatment of Class II Division 2 Malocclusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Class II Div 2 Incisal Relationship
Keywords: Class II division 2
Alignment
Leveling
Lead sponsor: Jordan University of Science and Technology
Sponsor class: OTHER
First posted: 2019-02-07
Enrollment: 54
Sex: ALL
Minimum age (years): 17
Maximum age (years): 26
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized clinical trial
Primary purpose: TREATMENT

Brief summary: The aim of this prospective study was to compare between two different treatment modalities of class II division 2; to start treatment in upper arch first until adequate overjet is obtained or to start in the lower arch first with removable anterior bite plane in upper arch.

Detailed description: Fifty four subjects with class II division 2 participated in this study. The subjects were randomly divided into two groups; Group one (28 patients): orthodontic treatment with upper arch bond up first and lower arch was bonded when 4 mm overjet was reached. The treatment continued until 0.019 x 0.025 " stainless steel wires were reached in both arches. Group 2 (26 patients): orthodontic treatment with lower arch bond up first with removable anterior bite plane in upper arch. When 0.019 x 0.025" stainless steel wire was reached, the upper arch was bonded. The treatment continued until 0.019 x 0.025" stainless steel wires were reached. Three cephalograms were taken for each patient in both groups; pretreatment (T0) , after bonding the other arch (T1) and at the end of leveling and alignment in both arches (T2). Cephalometric measurements and superimpositions were made. Skeletal and dentoalveolar treatment changes were compared within and between the 2 groups.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 17 years and ≤ 26 years
* Class II division 2 malocclusion.
* Overjet (OJ) \< 4 mm.
* Overbite (OB) covering more than half of the lower incisor height.
* Mild to moderate crowding with tooth contact displacement no more than 2 mm.
* Good oral hygiene and healthy periodontium.

Exclusion Criteria:-

* Systemic health problems and medications were taken.
* History of previous orthodontic treatment.

Primary outcomes:
measure: Upper and lower incisors proclination
timeFrame: 2 years
Secondary outcomes:
measure: Duration of treatment
timeFrame: 2 years
measure: Pain perception
timeFrame: 2 years
Other outcomes:
Locations:
city: Irbid
country: Jordan
facility: Jordan University of Science and Technology Dental Teaching Clinics
Study officials:
affiliation: Jordan University of Science and Technology
name: Susan AlKhateeb, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01626339: Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
Official title: Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Age Related Macular Degeneration
Keywords: Anti vascular endothelial growth factor
retinal vessels
Lead sponsor: University of Malaya
Sponsor class: OTHER
First posted: 2012-06-22
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye


Eligibility criteria: Inclusion Criteria:

• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

Exclusion Criteria:

* History of previous systemic or ocular Anti-VEGF therapy
* History of previous intravitreal injection with any drug
* Intraocular pressure ≥ 22
* Glaucoma
* History or presence of thromboembolic events
* Un-controlled blood pressure
* Blood donation during the previous 3 weeks
* Relevant media opacity of the lens

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kuala Lumpur
country: Malaysia
facility: University of Malaya Medical Center
Study officials:
References:
Clinical trial NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
Official title: Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Stomach Cancer
Gall Bladder Cancer
Bile Ductus Cancer
Pancreas Cancer
Colorectal Cancer
Keywords: Stomach cancer
Gall bladder cancer
Bile ductus cancer
Pancreas cancer
Colorectal cancer
Chemo radiotherapy
Phase I-II
Oxaliplatin
Capecitabine
Response
Lead sponsor: Lund University Hospital
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
name: Sanofi-Synthelabo
First posted: 2009-11-19
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors. The trial consists ot two separate studies; CORGI-U in patients with stomach- bile ducts- gallbladder and pancreas cancer, and CORGI-L in patients with colorectal cancer.

CORGI-U will be designed as a phase-I-II-study,in which the first part will be a chemotherapy dose finding study, followed by a phase II part to establish response rates. All subjects receives radiotherapy concommitant.

CORGI-L is a phase II trial, in which patients are treated with chemotherapy at fixed doses with radiotherapy concommitant.


Eligibility criteria: Inclusion Criteria:

* Over 18 years of age
* Measurable disease according to RECIST
* ECOG Performance Status 0-1
* ANC over 1.5 x 10 9/L
* Platelets over 100 x 10 9/L
* Creatinine less than 1.5 x ULN
* Bilirubin less than 1.5 x ULN
* ALT less than 2.5 x ULN
* Signed informed concent

Exclusion Criteria:

* Prior radiotherapy to the same local
* Prior chemotherapy for locally advanced or metastatic disease
* Pregnancy or breast feeding
* Peripheral neuropathy more than grade 1
* Uncontrolled diarrhéa
* Other serious uncontrolled concomitant illness
* Lymph node metastasis that can not be included in the GTV (gross tumor volume), without exceeding the stipulated radiotherapy doses in organs at risk

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Karlstad
country: Sweden
facility: Centralsjukhuset, Dept of Oncology
city: Lund
country: Sweden
facility: University Hospital Lund
city: Malmö
country: Sweden
facility: University Hospital Malmö, Dept of Oncology
city: Stockholm
country: Sweden
facility: Karolinska University Hospital
city: Uppsala
country: Sweden
facility: Akademiska Sjukhuset
Study officials:
affiliation: University Hospital Lund
name: Anders Johnsson, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01041339: ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?
Official title: ST Elevation (Acute Coronary Syndrome Versus Pericarditis;Could Measurement of Lp-associated PLA2 -a Vascular Specific Marker of Inflammation- be Helpful to the Clinician?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Chest Syndrome
Keywords: LpPLA2
ST elevation
acute pericarditis
Lead sponsor: Wolfson Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-12-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: acute chest pain patients admitted to ICCU with acute ST elevation and elevated troponin

Brief summary: A blood test (2-3 cc peripheral venous blood) drawn /used from already available required lab tests to distinguish between pericarditis accompanied with electrocardiogram (ECG) signs mimicking infarction. A test of clinical potential if proven to be able to support either origin of acute chest pain etiology.

Detailed description: Too many times young patients presenting with acute chest pain are referred to invasive angiography or treated with anticoagulation therapy a measure of detrimental effect in those inflicted with acute pericarditis.

A simple blood test (the PLAC test) may have some value in aiding rapid diagnosis saving need for cath.

Eligibility criteria: Inclusion Criteria:

* acute chest pain
* acute ST elevation
* elevated troponin I

Exclusion Criteria:

* patients with recent (\> 24 hour chest pain) myocardial infarction
* refusing to provide blood samples

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Holon
country: Israel
facility: The E.Wolfson MC
Study officials:
affiliation: The E.Wolfson MC
name: Alexander J Izhaki, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02739139: Efficacy Study of AlphaBRAIN Administered Orally
Official title: Randomized Double-blind, Placebo-Controlled, Parallel Group, Efficacy Study of AlphaBRAIN(TM) Administered Orally
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cognitive Functioning
Lead sponsor: Onnits Labs, LLC
Sponsor class: INDUSTRY
First posted: 2016-04-15
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The manufacturers of AlphaBRAIN(TM) claim that their product, when taken as directed, has beneficial effects on cognition. The active ingredient in AlphaBRAIN, Huperzine A, is a naturally occurring compound found in firmoss and also thought to be an acetylcholinesterase inhibitor. Numerous clinical studies have been undertaken to investigate the effects of Huperzine A on cognition and have demonstrated benefit to cognition in both individuals diagnosed with neurodegenerative diseases as well as performance on academic tasks by students. However, to our knowledge, there are no randomized controlled trials evaluating the effects of AlphaBRAIN(TM) on cognition. Thus, the purpose of the current study is to assess the effects of daily oral administration of AlphaBRAIN(TM) on cognitive functioning, as compared to placebo, after 45 days of treatment.

1. To evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on the change in a battery of standardized neuropsychological tests (see attached).
2. A secondary objective is to evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on sleep.


Eligibility criteria: Inclusion Criteria:

* Community dwelling and can provide informed consent.
* MMSE score of ≥ 26.
* Body Mass Index within two standard deviations of the norm.
* Fluent in English.
* Willing to complete all study assessments.
* Adequate visual and auditory acuity to allow for neuropsychological testing.

Exclusion Criteria:

* MMSE score \< 26
* Body Mass Index greater then two standard deviations from the norm.
* Visual or Auditory disability which would interfere with neuropsychological testing.
* No past diagnosis of Stroke, ADD/ADHD, Learning Disability or Cardiac Condition.
* No current life threatening illnesses.
* Not currently (past 60 days) taking antidepressants or other psychoactive medications.
* Not currently taking any non-prescription cognitive enhancers (nutraceuticals or vitamins such as Ginko biloba.
* No history of alcohol or drug or dependence as defined by the DSM-IV-TR.

Primary outcomes:
measure: Performance on Standardized Neuropsychological Battery (Verbal Memory; Executive Functioning; Visual Memory; Working Memory; Attention; Processing Speed)
timeFrame: Six Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chestnut Hill
country: United States
facility: Boston Center for Memory
state: Massachusetts
Study officials:
References: